Non-arteritic Ischemic Optic Neuropathy Clinical Trial
— Pilot-SINNOfficial title:
Pilot SINN; Assessment of Visual Field (vf)-Related Endpoints in Patients With Non-arteritic Ischemic Optic Neuropathy (N-AION)
Verified date | May 2014 |
Source | University Hospital Tuebingen |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Ethics Commission |
Study type | Observational |
This present research project intends to collect five quantitative test series:
- perimetric examination using static stimuli, assessing the entire (80 degree) visual
field with a fast thresholding algorithm (GATE) [Schiefer 2008] to know the extent/
magnitude of the visual field defect and its variability within the cohort and over
time
- D-BCVA, using FrACT [Bach 2007] and EDTRS chart [Ferris 1982]
- RAPD (using swinging flashlight test).
- IOP (using applanation tonometer)
- RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm, and volume scan) Optic
disk morphology will be documented by fundus photography. This assessment of the
above-mentioned data is needed in order to allow for estimation of the spontaneous
course / fluctuation of the (quantified) functional and morphometric parameters of the
N-AION patients during the follow-up period. This is essential for the estimation of
the sample size of the subsequently intended SINN study, that is intended to compare
different therapeutic strategies in N-AION patients.
Status | Completed |
Enrollment | 16 |
Est. completion date | February 2011 |
Est. primary completion date | February 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: - physical, intellectual and linguistic abilities, in order to
understand the test requirements - willingness to comply with the protocol (4 visits) - 41 - 80 years, informed consent - acute N-AION (< 7 d) - D-BCVA > 0.1 (2/20) - RAPD = 0.3 logE steps (neutral density filters) and: - spherical ametropia max. ± 8 dpt, cylindrical ametropia max. ± 3 dpt - isocoria, pupil diameter > 3 mm Exclusion Criteria: - diabetic retinopathy and any other orbital, intracranial or optic nerve disease - history of epilepsy or significant psychiatric disease - medications known to affect visual field sensitivity - infections (e.g. keratitis, conjunctivitis, uveitis) - severe dry eyes - miotic drug - amblyopia - strabismus - any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields, disc imaging or accurate IOP readings - cataract with relevant impairment of vision - keratoconus - intraocular surgery (except for uncomplicated cataract surgery) performed < 3 month prior to screening - history or signs of any visual pathway affection other than N-AION - history or presence of macular disease and / or macular edema - ocular trauma |
Observational Model: Case Control, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Germany | Centre for Ophthalmology Institute for Ophthalmic Research University of Tübingen | Tübingen | Baden-Württemberg |
Lead Sponsor | Collaborator |
---|---|
University Hospital Tuebingen | University Hospital Freiburg |
Germany,
Kernstock C, Beisse F, Wiethoff S, Mast A, Krapp E, Grund R, Dietzsch J, Lagrèze W, Fischer D, Schiefer U. Assessment of functional and morphometric endpoints in patients with non-arteritic anterior ischemic optic neuropathy (NAION). Graefes Arch Clin Exp — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assessment of visual field (VF)-related endpoints in patients with non-arteritic ischemic optic neuropathy (N-AION) | This present research project intends to collect five quantitative test series in order to allow the estimation of the spontaneous course / fluctuation of the (quantified) functional and morphometric parameters of the N-AION patients during the follow-up period. This is essential for the estimation of the sample size of the subsequently intended SINN study, that is intended to compare different therapeutic strategies in N-AION patients | 2 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06031350 -
Peripapillary and Macular Vascular Changes of Unilateral Anterior Ischemic Optic Neuropathy: An Optical Coherence Tomography Angiography Study
|
||
Completed |
NCT02045212 -
Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
|
Phase 2 | |
Completed |
NCT03758118 -
Citicoline in Non-Arteritic Ischemic Optic Neuropathy
|
N/A | |
Recruiting |
NCT05305079 -
NA-AION Risk Factors: New Perspectives
|